Suspending vascular endothelial growth factor inhibitors in eyes with retinal vein occlusion
British Journal of Ophthalmology · 13.05.2026 · bjo-2025-328709
DOI: 10.1136/bjo-2025-328709 ↗Kurz gefasst
Fachartikel in der Zeitschrift British Journal of Ophthalmology, online erschienen am 13.05.2026. Verfasst von Adrian Robert Hunt und 10 weiteren Autor:innen. Beteiligte Einrichtung: Ophthalmology, Westmead Hospital, Westmead, New South Wales, Australia adrianhunt@eyesurgeonsmiranda.com.au. Die Arbeit nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Health and Medical Research Council, Australia, Royal Australian NZ College of Ophthalmologists Eye Foundation.
Abstract (Originalsprache)
Background/Aims To identify predictors of continued discontinuation of vascular endothelial growth factor (VEGF) inhibitors for retinal vein occlusion (RVO) after it has been suspended.
Methods
Eyes with RVO were identified in the Fight Retinal Blindness! registry that suspended VEGF inhibitors for ≥180 days when visual acuity (VA) was ≥35 letters, from 1 December 2011–2021. The primary outcome was not resuming therapy through 24 months which defined success.
Results
Half (186/362 (51%)) of the eligible 6-month suspensions successfully continued through 24 months. Successful cessation attempts began earlier (9 vs 14 months; p=0.001), after greater VA improvement (mean, +12.6 vs +8.5 letters; p=0.01) following more injections in the first 6 months (median, 5 vs 4; p
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Ophthalmology, Westmead Hospital, Westmead, New South Wales, Australia adrianhunt@eyesurgeonsmiranda.com.au.
- Save Sight Institute, The University of Sydney Faculty of Medicine and Health, Sydney, New South Wales, Australia.
- Mater Private Hospital, Dublin, Leinster, Ireland.
- Ophthalmology, Isala, Zwolle, The Netherlands.
- Australian Eye Specialists, Wyndham, New South Wales, Australia.
- Sydney Retina Clinic, Sydney, New South Wales, Australia.
Förderung
- National Health and Medical Research Council, Australia
- Royal Australian NZ College of Ophthalmologists Eye Foundation
Zitieren
APA
Hunt, A. R., Hashimoto, Y., O'Toole, L., Ponsioen, T. L., Jaross, N., Fraser-Bell, S., Kusenda, P., Alforja, S., Barthelmes, D., Gillies, M. C., & Fight Retinal Blindness! Investigators (2026). Suspending vascular endothelial growth factor inhibitors in eyes with retinal vein occlusion. British Journal of Ophthalmology, bjo-2025-328709. https://doi.org/10.1136/bjo-2025-328709
Vancouver
Hunt AR, Hashimoto Y, O'Toole L, Ponsioen TL, Jaross N, Fraser-Bell S, et al. Suspending vascular endothelial growth factor inhibitors in eyes with retinal vein occlusion. British Journal of Ophthalmology. 2026:bjo-2025-328709. doi:10.1136/bjo-2025-328709
BibTeX
@article{Hunt2026,
author = {Hunt, Adrian Robert and Hashimoto, Yohei and O'Toole, Louise and Ponsioen, Theodorus Leonardus and Jaross, Nandor and Fraser-Bell, Samantha and Kusenda, Pavol and Alforja, Socorro and Barthelmes, Daniel and Gillies, Mark C and Fight Retinal Blindness! Investigators, Fight Retinal Blindness! Investigators},
title = {Suspending vascular endothelial growth factor inhibitors in eyes with retinal vein occlusion},
journal = {British Journal of Ophthalmology},
year = {2026},
pages = {bjo--2025--328709},
doi = {10.1136/bjo-2025-328709}
}
EUVIMED